Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad from March 20 to 24, 2023. The inspection has been classified as Voluntary Action Indicated (VAI). The EIR report indicates that the inspection is closed.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 582.75 as compared to the previous close of Rs. 582.05. The total number of shares traded during the day was 40561 in over 2201 trades.

The stock hit an intraday high of Rs. 587.45 and intraday low of 578.20. The net turnover during the day was Rs. 23617667.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals EIR USFDA SEZ1 ManufacturingFacility Pharmez Ahmedabad